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Trypanosomabrucei,thecausativeagentofhumanAfricantrypanosomiasis,affectstensofthousandsof
sub-Saharan Africans. As current therapeutics are inadequate due to toxic side effects, drug resistance,
and limited effectiveness, novel therapies are urgently needed. UDP-galactose 40-epimerase (TbGalE),
an enzyme of the Leloir pathway of galactose metabolism, is one promising T. brucei drug target. We
here use the relaxed complex scheme, an advanced computer-docking methodology that accounts for
full protein flexibility, to identify inhibitors of TbGalE. An initial hit rate of 62% was obtained at
100 μM, ultimately leading to the identification of 14 low-micromolar inhibitors. Thirteen of these
inhibitorsbelongtoadistinctserieswithaconserved bindingmotifthatmayproveusefulinfuturedrug
design and optimization.
Introduction
Human African trypanosomiasis (HAT
a), a condition
caused by Tsetse-fly mediated transmission of the unicellular
parasite Trypanosoma brucei (T. brucei),
1 affects between
50000 and 70000 people living in sub-Saharan Africa, with
an additional 50 million people at risk of infection.
2 The
initial stage of the disease, called the hemolymphatic stage,
ischaracterizedbymildsymptomsincludingfever,arthralgia,
headache, and pruritus. Once the parasite crosses the blood-
brain barrier, the neurological symptoms of the chronic stage
of the disease are manifest, including severe headaches, noc-
turnal insomnia, mental and psychological disturbances,
coma, and death if untreated.
2
Pentamidine and suramin, effective against the subspecies
T. b. gambiense and T. b. rhodesiense, respectively, are typi-
cally administered during the early hemolymphatic stage.
3-5
ThetreatmentsrecommendedbytheWorldHealthOrganiza-
tion for advanced HAT, however, melarsoprol and eflor-
nithine, are entirely inadequate. Melarsoprol causes ence-
phalopathy in 1 out of every 20 recipients and is subject to
growing drugresistance.
2,6,7Eflornithineisineffectiveagainst
the T. b.rhodesiense subspecies
8 and cancausefever, seizures,
andinfections,althoughcombinationtherapywithnifurtimox
ameliorates some of these side effects.
9 To date, no vaccine is
available because T. brucei undergoes antigenic variation by
altering its surface glycoprotein coat, thereby evading the
immune system.
10
As drugs that target the infections of the developing world
are rarely profitable, pharmaceutical companies have largely
neglected the developmentof novelHAT therapeutics.Ofthe
drugs listed above, for example, only one, eflornithine, has
been developed since the late 1940s.
11 The trypanocidal effect
of eflornithine was discovered only after it failed as an
antineoplastic agent,
12 and it is only available today because
the compound has also been commercialized as a cosmetic
cream for the treatment of hirsutism.
Thisneglectprovidesresearchersinacademiawithaunique
opportunity to step in and address a largely unmet need.
While a few academic institutions do perform high-through-
putscreenstoidentifynovelinhibitorsofpathogenicenzymes,
these large-scale projects are often cost prohibitive outside of
industry. Fortunately, recent advances in computer-aided
drug design have provided academic researchers with power-
fultoolsthatinpartcompensateforinsufficientfunding.
13-15
Motivated by the urgent need for novel HAT therapeutics,
computer-aided drug design is here used to identify 14 low-
micromolar inhibitors of T. brucei UDP-galactose 40-epimerase
(TbGalE, alsoknown asUDP-glucose 40-epimerase),a short-
chaindehydrogenase/reductaseenzymeoftheLeloirpathway
of galactose metabolism.
16,17 TbGalE is essential for parasite
survival, as null mutants of both the bloodstream and pro-
cyclic form of the parasite are not viable.
18,19 In T. brucei,
galactose is a component of the variant surface glycoproteins
used for immune-system evasion,
20of the transferrin receptor
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used for iron acquisition,
21 and of the parasite endocytic
pathway.
21Curiously,whileT.bruceihasahexosetransporter
capable of glucose uptake, it is unable to acquire galactose
from the host;
22,23 intracellular galactose must be synthesized
from glucose via TbGalE. Consequently, we are hopeful that
the compounds presented here, which inhibit this key step
of trypanosomal galactose synthesis, may serve as useful
scaffolds for future drug design and optimization.
Results/Discussion
Human African trypanosomiasis threatens 50 million
peopleinsub-SaharanAfrica.
2Ascurrent therapiesareeither
toodangerousortoolimited,noveldrugsareurgentlyneeded.
UDP-galactose 40-epimerase (TbGalE), a protein critical to
T. brucei survival, is one potential drug target. We here use
computer-aided drug design to identify 14 low-micromolar
inhibitors of TbGalE.
Computer Docking and Protein Dynamics. Traditional
computer-docking methodologies often fail to identify true-
positive inhibitors because the static protein structures typi-
callyuseddonotcapturethehighlydynamicrealityofsmall-
moleculebinding.
24,25Whenaligandapproachesitsreceptor
in vitro or in vivo, itencounters not a static protein structure
but rather an ensemble of structures as the protein “breathes”
in solution. Upon ligand binding, the population of receptor
active-site configurations sampled by the protein may shift
to better accommodate the ligand. Additionally, under the in-
fluence of a bound ligand, the protein may assume novel active-
site configurations not sampled by the apo protein at all.
26
To better understand TbGalE dynamics, we performed
five 20 ns molecular dynamics (MD) simulations. Five short
simulations were chosen, as opposed to one long simulation,
in order to increase the diversity of protein conformations
sampled and to ensure that the conformations sampled were
geometrically similar to the known crystal structure. As
TbGalE is a homodimer, each simulation provided two
monomer trajectories, further increasing the diversity of
conformations sampled. Clustering was subsequently used
to identify 24 protein structures with active sites representa-
tive of the many active-site configurations sampled during
the MD simulation. These 24 representative protein struc-
tures are said to constitute an ensemble.
The protein conformations of the ensemble proved useful
in subsequent computer-docking studies.
27 Recently, a new
dockingprotocolcalledtherelaxedcomplexscheme(RCS)
25
has been developed that takes into account full protein
flexibility. Rather than docking candidate compounds into
a static protein receptor, compounds are docked into an
ensemble of protein conformations typically extracted from
an MD simulation. The compounds are then ranked by an
ensemble-basedscorethataccountsforactive-sitedynamics.
The RCS has already been used to successfully identify
inhibitors of FKBP,
28 HIV integrase,
29 and T. brucei RNA
editing ligase 1.
30
In the current work, we used AutoDock Vina (Vina)
31 to
perform a RCS screen of the NCI Diversity Set II into the 24
ensemble conformations extracted from theMD simulation.
Like previous versions of AutoDock, Vina is freely available
to the academic community. Additionally, it is 2 orders of
magnitude faster than AutoDock 4.0 (AutoDock),
32 the pre-
vious version. Vina performs well relative to AutoDock; while
AutoDock is slightly better at predicting the energy of binding
(standard error of 2.2 kcal mol
-1 versus 2.8 kcal mol
-1),
Vinamoreaccuratelyreproducescocrystallizedligandposes.
31,32
To our knowledge, Vina has never been used in a RCS screen.
Compounds were docked into both the UDP-glucose
and NAD
þ binding pockets and were ranked by both an
ensemble-average and an ensemble-best scoring scheme
(Supporting Information). Twenty-six high-scoring com-
pounds were subsequently tested experimentally.
Experimental Validation Confirms Multiple Hits from the
Primary Screen. Of the26compounds oftheprimary screen,
10 showed >50% average inhibition at 100 μM. Interest-
ingly, at this same concentration, six compounds showed
greater than 2-fold stimulation, suggesting allosteric coop-
erativity between the two monomers of the TbGalE homo-
dimer, in harmony with previous studies that demonstrated
GalE allostery in Kluyveromyces fragilis and Saccharomyces
fragilis.
33,34Aswedonotexpectcomputerdockingtobeable
to distinguish between an agonist and an antagonist, the
effective hit rate of the primary screen was therefore 62% at
100 μM.
The 10 100-μM inhibitors were subsequently tested at
10 μM. Three showed >∼50% average inhibition; com-
pounds 1, 2, and 3 (clorobiocin) had IC50 values of 3.6 (
0.8, 5.6( 0.8,and5.0(1.2μM,respectively, andHill slopes
of 1.8 ( 0.6, 1.2 ( 0.3, and 2.1 ( 0.5, respectively (Tables 1
and S1 in Supporting Information). Interestingly, com-
pounds 1 and 2 share a 20-(phenylcarbamoyl)-[1,10-
biphenyl]-2-carboxylic acid core scaffold.
In one recent study, 95% of the inhibitors identified in a
high-throughput screen acted through a nonspecific aggre-
gation-based mechanism. This same study suggested that
aggregation-based inhibition typically produces steep Hill
slopes that are much greater than unity, with average values
around 2.2.
35 As the Hill slopes of compounds 2 and 3
(clorobiocin) were significantly greater than unity (Table
S1, Supporting Information), TbGalE inhibition was me-
asured at 30 μM inhibitor concentration (∼5   IC50) in the
presence and absence of a detergent that disrupts colloidal
aggregates (0.06% n-octylglucopyranoside). No significant
differences in inhibition were noted, suggesting that inhibi-
tion is specific rather than aggregation-based.
30 Given that
the possibility of aggregation was eliminated, the steep Hill
slopes of these two compounds provide further evidence
for allostery between the two monomers of the TbGalE
dimer.
36,37
Clorobiocin: An Interesting Inhibitor. One of the hits from
the primary virtual screen, compound 3 (clorobiocin), an
aminocoumarin derived from several Streptomyces species,
has previously been shown to inhibit the growth of Trypano-
soma cruzi (T. cruzi), a close relative of T. brucei.
38 As
clorobiocin is a known bacterial topoisomerase II inhibitor,
some have hypothesized that topoisomerase II may be the
T. cruziprotein target aswell,
39 although other targetscould
not be ruled out.
38 The current work suggests that UDP-
galactose 40-epimerase may also be among the proteins
targetedbythisapparentlypolypharmacophoriccompound.
We note with interest that novobiocin, a compound
structurally similar to clorobiocin that likewise inhibits the
growth ofT. cruzi,
38 didnotshow greater than50%TbGalE
inhibition at 10 μM despite the fact that our computational
model predicted high binding affinity. The crude scoring
function employed by Vina, optimized not only for accuracy
but also for speed, seems unable to differentiate between the
apparently subtle differences in the protein-ligand interac-
tions of clorobiocin and novobiocin.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 5027
Table 1. The 14 Low-Micromolar TbGalE inhibitors Indentified
a
aThe first column shows compound structures, and the second column shows the compound identification number used throughout the text. The
thirdcolumnshowstheIC50valueofeachcompoundasmeasuredinenzymaticassays.ThefourthandfifthcolumnsshowtheEC50valuesasmeasuredin
whole-cell assays of T. brucei and human MRC5 cells, respectively. The final column shows the predicted LogP value of each compound.5028 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Durrant et al.
PredictedBindingPosesofTopInhibitors.Computerdock-
ing suggests that compound 3 (clorobiocin) occupies the
NAD
þ-binding pocket. To further characterize the cloro-
biocin binding pose, we examined the Vina scores of clor-
obiocindockedintoeachoftheproteinconfigurationsofthe
ensemble and selected the binding pose/protein configura-
tion associated with the best score for further analysis. The
predicted protein-ligand interactions are represented sche-
matically in Figure 1.
Clorobiocin is predicted to participate in multiple hydro-
genbondswiththebackboneatomsofaminoacidsliningthe
NAD
þ binding pocket. One ligand hydroxyl group is pre-
dicted to form two hydrogen bonds with the backbone
amines of N202 and A203; a second ligand hydroxyl group
is predicted to form hydrogen bonds with the backbone
amines of V35, G36, and S33. Finally, a ligand secondary
amine is predicted to form a hydrogen bond with the back-
bone carbonyl oxygen atom of A100. We note again, how-
ever, that many of these same protein-ligand interactions
characterize the predicted binding mode of novobiocin as
well, despite the fact that novobiocin binding to TbGalE is
weak.
The binding modes of compounds 1 and 2, both predicted
to bind in the UDP pocket, were not so paradoxical. These
compounds contain similar 20-(phenylcarbamoyl)-[1,10-
biphenyl]-2-carboxylic acid core scaffolds (Table 1) and
similar predicted binding modes (Figure 2). For each of
these two ligands, we again examined the Vina scores of
the ligand docked into the various protein configurations of
the ensemble and selected the binding pose/protein config-
uration associated with the best score for further analysis
(Figure 2). Thecore scaffold common tocompounds 1and 2
participates in many of the same hydrogen bonds that
characterize UDP-glucose binding. R335, N202, and R268
all form hydrogen bonds with the diphosphate moiety of
UDP-glucose; they likewise form hydrogen bonds with the
carboxylate group andthe carbonyloxygen atom ofthe core
scaffold.Additionally,H221mayalsoformahydrogenbond
with the carboxylate group of the core scaffold (Figure 2).
Cation-π interactions seem to play a critical role in the
binding of compounds 1 and 2. In these interactions, the
positive charge of the cation is electrostatically attracted to
the quadrupole moment of an aromatic group.
40 If the
predicted binding of the core scaffold of compounds 1 and
2 is correct, both R335 and R268 participate in cation-π
interactions with the ligand.
Compounds 1 and 2 have polyaromatic moieties that
extend into the pocket normally occupied by the uridine
and ribose moieties of UDP-glucose. Much work can yet be
donetooptimizethesefusedringsystemsinordertoimprove
binding,ashintedatbythehydrogenbondpredictedtoform
between compound 1 and the backbone carbonyl oxygen
atomofT220(Figure2a).Otherpotentialinteractinggroups
in the uridine and ribose portions of the UDP-glucose
binding pocket include the backbone carbonyl oxygen atom
of P253 and the backbone amine of F255. It may also be
possible to add moieties to the fused ring system that exploit
the F255 aromatic side chain, which can participate in π-π
and cation-π interactions.
Finally, the nucleophilic side-chain thiol of C266 is
attractive from a drug-design perspective; fragments with
Figure 2. The predicted binding modes of compounds 1 and 2. Some portions of the protein have been removed to facilitate visualization.
Hydrogen bonds between the protein and ligand are shown as black lines.
Figure 1. Thepredicted ligand-proteininteractions ofclorobiocin
bound to TbGalE, shown schematically.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 5029
electronegative moieties could be added to the fused ring
systems of compounds 1 and 2 in order to facilitate the
formation of a covalent adduct with the C266 thiol group, a
strategy similar to that employed by Kerr et al. in designing
potent vinyl-sulfone inhibitors of parasitic cysteine pro-
teases, including K777, which, pending FDA approval,
will soon enter phase I clinical trials.
41 Additionally, as this
cysteine is a glycine in HsGalE, compounds that target C266
may be selective for the trypanosomal form of the enzyme,
although caution is advised as nonspecific reactions with
protein thiols could lead to toxic side effects.
The Secondary Virtual Screen: A Similarity Search. En-
couraged by these initial results, we next searched the entire
NCI database for compounds similar to the three low-
micromolar inhibitors verified experimentally. Eighty addi-
tional compounds were subjected to the same RCS protocol
used in the primary virtual screen, and 14 novel compounds
were thus identified as potential binders. One of these
compounds, kedarcidin, a structural orthologue of cloro-
biocin,wasunavailablefromtheNCI,andanotherfailedthe
purity criteria. Thus, 12 compounds were subsequently
tested experimentally.
Eleven of the 12 compounds showed >50% average
inhibition at 10 μM. Subsequent experimental analysis con-
firmed that these compounds had IC50 values between 0.9
and6.8μM(Table1).Aspreviously,aggregationeffectswere
excluded,andcompoundidentityandpuritywereconfirmed
by accurate mass and LC-MS.
Taken together with the compounds of the initial screen,
these inhibitors constitute a novel hit series based on a
20-(phenylcarbamoyl)-[1,10-biphenyl]-2-carboxylic acid scaf-
fold. Additionally, a singleton hit (clorobiocin) was also
found to be potent, although novobiocin, a related com-
pound that might have otherwise been considered a member
of the same hit series, was not.
Whole-Cell Assays. All low-micromolar TbGalE inhi-
bitors identified were tested for their ability to inhibit the
growth of cultured T. brucei and human liver MRC5 cells
using the established Alamar Blue protocol.
42,43 Two com-
pounds containing the 20-(phenylcarbamoyl)-[1,10-biphenyl]-
2-carboxylic acid core scaffold, compounds 12 and 13,h a d
EC50 values of 24.4 and 28.5 μM against whole-cell T. brucei,
respectively. Additionally, the natural product clorobiocin
(compound 3) had an EC50 value of 4.4 μM. Only compound
14, a compound with no activity against whole-cell T. brucei,
demonstrated inhibition of MRC5 growth (Table 1).
To better understand why most of the TbGalE inhibitors
failed to inhibit whole-cell T. brucei, we calculated the LogP
value of each (Table 1, Supporting Information). With only
one exception, the logP values were all high, either near the
upper bound for what is considered “druglike” or, in several
cases, well beyond that bound.
44,45 As these compounds are
very hydrophobic, we postulate that they are retained in the
cellular membrane, explaining the reduced efficacy against
whole-cell T. brucei. The one compound with a druglike
LogP value was compound 3 (clorobiocin), which has a
measured whole-cell EC50 of 4.4 μM, suggesting inhibition of
intracellular targets including TbGalE and, potentially, topoi-
someraseII.
39Asanalternateexplanationforpoormembrane
traversal, we note also that the charged carboxylate moiety
characteristic of the main hit series, absent in clorobiocin, may
likewise block access to intracellular targets.
Designing compounds similar to those based on the
20-(phenylcarbamoyl)-[1,10-biphenyl]-2-carboxylic acid core
scaffold but with reduced hydrophobicity should not be
difficult. We note that these inhibitors have roughly the
same IC50 values regardless of the fused ring system that is
attachedtothecorescaffold.Thissuggeststhatthefusedring
systems likely contribute to the overall binding affinity
principallythroughnonspecificinteractions,ifatall.Hydro-
philic functional groups could likely be added to the fused
ring systems without compromising the overall binding
affinity, therebyincreasingthepropensityofthesemolecules
to traverse cellular membranes.
Several of the fused ring systems have functional groups
thatmaybeamenabletochemicalmodification.Hydrophilic
moieties could be added to the fused ring systems of com-
pounds 1 and 6 via substitution at the hydroxyl group,
for example. Several of the TbGalE inhibitors identified
also have aromatic halides that could facilitate fragment
addition.
As these compounds are already quite large, however, a
better approach may be to entirely substitute the fused ring
systems of the compounds tested here with other more
hydrophilic molecular fragments. Reactions between the
readilyavailablecompound[1,10-biphenyl]-2,20-dicarboxylic
acid (NSC1966) and varied aromatic and even nonaro-
matic amines could expand the chemical series explored
heretoincludecompoundswithmorefavorablepartition
coefficients.
If the above modifications fail to produce high-affinity
inhibitors of cellular growth, the charged carboxylate of the
main-series compounds could be methylated to potentially
facilitate membrane traversal. Once in the cell, this prodrug
could perhaps be demethylated by cellular esterases.
46
Conclusion
Inthecurrentstudy,weusedcomputer-aideddrugdesignto
identify 14 inhibitors of TbGalE, a potential T. brucei drug
target.AsnovelHATtherapeuticsareurgentlyneeded,weare
hopeful that the hit series described here will serve as a useful
scaffold for further drug optimization.
Our study also demonstrates the utility of the RCS. Ac-
countingforreceptorflexibilitywhenpredictingsmall-molecule
protein inhibition is clearly important, as one of the primary-
screen inhibitors would not have been identified had we con-
ducted a virtual screen against the crystal structure alone
(Supporting Information). We also show that both the ensem-
ble-average and the ensemble-best docking scores are useful
RCS ranking metrics (Supporting Information).
The chemical series of TbGalE inhibitors based on a 20-
carbamoyl-[1,10-biphenyl]-2-carboxylate core scaffold is pro-
mising. Future efforts should focus on improving target and
cellularpotency. Asthe fused ringsystems seem tocontribute
to ligand binding only nonspecifically, if at all, they could
potential be replaced. The side-chain thiol of C266, which
comeswithin4A ˚ ofthepredictedbindingmodeofcompound
2, could also be exploited for more specific binding. As this
cysteine is absent from the active site of the corresponding
humanprotein,inhibitorsthatexploitC266mayalsobemore
pathogen specific.
Experimental Section
System Preparation. Chains A and B of a 2.0 A ˚ resolution
TbGalE crystal structure (PDB ID: 1GY8
16) were processed for
use in a molecular dynamics simulation. All crystallographic
waterswithin4A ˚ oftheproteinwereretained,andmissingloops5030 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Durrant et al.
were modeled using Discovery Studio 2.1 (Accelrys). Hydrogen
atoms were added to the protein residues using the PDB2PQR
server;
47 histidine protonation states were manually verified.
Additional hydrogen atoms were added to the ligand and
cofactor using Discovery Studio 2.1 (Accelrys).
Force-fieldparametersforNAD
þ wereobtainedfromRichard
B. Ryce.
48,49 Atom-type parameters for uridine diphosphate
(UDP) werederived from the ff99 force field based on the uridine
monophosphate (RU) residue.
50 The linking ribose oxygen atom
of RU was replaced with a hydroxyl group, and the atom types of
the UDP β phosphate were chosen to be the same as those of the
RURphosphate. Ab initio partial charges were calculated for the
UDP atoms using the GAUSSIAN03 computer program. The
Hartree-Fock (HF) method, in conjunction with the 6-31þG*
basis set, was used for geometry optimization. The optimized
structure was used for subsequent single-point charge calcula-
tions performed using multiconformational RESP fitting.
51 The
remaining proteinresidues wereparametrized using the ff99 force
field.
50
The LEAP module of AMBER9 was subsequently used to
further process the system.
52 The protein was submerged in a
TIP3P
53water boxthat extended10 A ˚ beyondthe protein in the
x,y,andzdirections.EighteenNa
þionswereaddedtobringthe
system to electrical neutrality. An additional 13 Na
þ and Cl
-
ions were added to simulate a 20 mM solution.
Molecular Dynamics (MD) Simulations. The system was
relaxed via a four-phase minimization protocol. In the first
phase, 5000 steps of minimization were applied to the hydrogen
atoms alone. In the second phase, 5000 steps of minimization
wereappliedtothehydrogenatoms,thewatermolecules,andall
ions. Ten thousand steps of minimization were then applied to
thehydrogenatoms,thewatermolecules,allions,andtheatoms
of the protein backbone. Finally, all atoms were minimized for
an additional 25000 steps.
A four-phase equilibration protocol was next used. Starting
fromthe minimized system, foursequential, 250-psMDsimula-
tions at 310 K were executed with harmonic restraining forces
of 4.0, 3.0, 2.0, and 1.0 kcal mol
-1 A ˚ -2 applied to the atoms of
the protein backbone for the first, second, third, and fourth
simulation, respectively.
Thisequilibratedsystemwasusedasthestartingpointforfive
distinct 20 ns, unrestrained, “productive” MD simulations.
Because TbGalE is a homodimer, 200 ns of monomer dynamics
were effectively simulated. A 2 fs time step was used. The tem-
perature and pressure of the system were maintained by Langevin
dynamics at 310 K and the hybrid Nose-Hoover-Langevin
piston method at 1 atm, respectively,
54 with period and decay
times of 100 and 50 fs, respectively. Long-range electrostatics
weretreatedusingtheparticlemeshEwaldalgorithm.
55Bonded
interactions were calculated at every time step. Nonbonded
interactions and full electrostatics were calculated every two
time steps. Bonds with hydrogen atoms were constrained using
the SHAKEH algorithm.
56 NAMD 2.6 was used to perform all
minimizations, equilibrations, and productive simulations.
57
ConformationalClustering.Toidentifyrepresentativeprotein
conformations sampled during the MD simulation, each of the
10 effective trajectories (five simulations times two monomers
persimulation)wereconcatenated,andthecompositetrajectory
was aligned by minimizing the root-mean-square difference
(rmsd) between the active-site atoms of each frame and the
correspondingatomsofthefirstframe.rmsdclusteringusingthe
gromosalgorithmasimplementedintheGROMOSþþanalysis
software
58,59 was used to identify representative structures. A
rmsd cutoff of 1.4 A ˚ produced 24 clusters. The centoid member
of each cluster was selected; the set of all 24 centroids, repre-
sentative of all the protein configurations sampled during the
MD simulation, is said to constitute an ensemble.
RelaxedComplexScheme.AutoDockVina(Vina)
31wasused
for all computer dockings, as that program was able to ade-
quately recapture the crystallographic poses of the ligand and
cofactor. To account for full protein-receptor flexibility, each
compound of the NCI Diversity Set II was docked into the 24
ensemble conformations. Four RCS screens were performed.
For three, both the UDP ligand and the NAD cofactor were
removed from the receptor, and the compounds of the NCI
Diversity Set II were docked into the UDP binding site, into the
NAD binding site, and into both contiguous sites simulta-
neously, respectively. For the fourth, the NAD cofactor was
maintained,andthecompoundsoftheNCIDiversitySetIIwere
docked into the UDP binding site.
The compounds were ranked according to two ensemble-
based criteria. As each compound was docked into 24 distinct
protein conformations, the compounds were first ranked by the
average of these 24 docking scores (ensemble-average). Next,
the compounds were ranked by the best of these 24 docking
scores (ensemble-best) (Supporting Information).
Similarity Searches. An online search utility provided by the
NCI(http://129.43.27.140/ncidb2/)wasusedtosearchtheentire
NCI database for compounds similar to those identified in the
primary RCS screen. Two methods were used to judge com-
pound similarity. First, a substructure search was performed to
identify 19 compounds that contained a 20-(phenylcarbamoyl)-
[1,10-biphenyl]-2-carboxylic acid substructure. Second, 57 similar
compounds were identified using a Tanimoto index
60 with a
90% cutoff. Finally, four additional compounds similar to cloro-
biocin were identified using a Tanimoto index with an 80%
cutoff.
TbGalEInhibitionAssay.Allcompoundswereobtainedfrom
the NCI/DTP Open Chemical Repository (http://dtp.cancer.gov).
Compound identity was independently confirmed by high-
resolution mass spectrometry, and LC-MS, which was used to
monitor both the negative and positive mode simultaneously in
the range 80-1000 m/z, confirmed purity >99% (i.e., all com-
pounds gave a single peak >99% that was of the correct mass).
Recombinant TbGalE containing an N-terminal hexahisti-
dine tag was expressed in Escherichia coli and purified as
described previously.
18 Theinhibition of TbGalE was measured
using high pH anion exchange chromatography (HPAEC) to
follow the conversion of UDP-Gal to UDP-Glc by TbGalE.
42
The reaction mixture (1 mM Tris pH 7.6, 100 μM UDP-Gal,
100 μM β-NADþ,5μg/mL TbGalE, 1% dimethyl sulfoxide)
was incubated at 37  C for 30 min with or without inhibitor
(0.03-100 μM), quenched with 15 μL of 10 mM NaOH, and
then subjected to HPAEC chromatography on a CarboPac PA-1
column(Dionex)in1mMNaOHwithaNH4OAcgradient.
42The
eluant was monitored at 260 nm and peaks assigned by compar-
isontocommercialstandards.TheIC50valuewascalculatedusing
a four-parameter fit of the potency curves derived from three
independent experiments.
To exclude the possibility of aggregation effects, the inhibi-
tion of the compounds was measured at 30 μM( ∼5   IC50)i n
the presence and absence of a detergent (0.06% n-octylglucopy-
ranoside), and no difference was observed.
Cytotoxicity Assay. Cytotoxicity assays were preformed
against cultured T. brucei and human MRC5 cells as described
previously,
42butfurtherminiaturizedto384wellplates.Briefly,
50 μL of cells (1   10
4 cells/ml) were aliquoted into 384-well
plateandincubatedwithorwithoutinhibitor(100μMto30nM)
for a further three days before the number of viable cells was
counted using the Alamar blue assay.
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